玩股撇步(動畫小學堂)  

  • 營業利益和稅後淨利成長率大於營收成長率, 通常代表公司在成長, 如果是漲很多的股票, 發現沒有這個現象就要留意了
  • 營收到某個數字後, 營業利益產生不成比例的增加, 有可能是規模經濟的效應
  • 如果是有淡旺季的公司, 是否有淡季不淡, 旺季更旺的情況
  • 漲很多的股票要留意 EPS 較上季是否有大幅衰退的情況
  • 如果EPS衰退,要觀察同業是不是有一樣的狀況
  • 要留意增資減資和公司債對股本及EPS的影響
成長能力-近20季
加權平均股數 QoQ YoYEPS QoQ YoY本業EPS QoQ YoY累計EPS QoQ YoY營收 QoQ YoY毛利率(%) QoQ YoY營業利益 QoQ YoY稅後淨利 QoQ YoY稅前淨利率(%) QoQ YoY稅後淨利率(%) QoQ YoY兩季平均(YOY)營收成長率(%)兩季平均(YOY)EPS成長率(%)兩季平均(YOY)本業EPS成長率(%)
23Q4 (20)2610.00.01.53-67.86139.060.13-97.08-85.2315.7210.7835.6334.19-25.247.7941.62-28.12-5.671.43-90.35-59.834.0-67.9138.114.86-56.6159.9611.70-57.05121.59-11.14-34.86-55.75
23Q3 (19)2610.00.04.76-1.86-40.284.45-14.42-44.4414.1950.4829.4745.732.95-15.1457.90-1.3-14.6814.82-8.18-43.8812.46-1.58-40.0734.25-0.17-29.8227.24-4.42-29.390.572.02-7.01
23Q2 (18)2610.00.384.855.9284.925.200.39246.679.43105.9217.5144.42-1.8152.6558.66-1.9923.7816.14-3.0229.3912.666.03285.9834.313.16134.0428.508.0153.1120.40310.76244.51
23Q1 (17)2610.00.384.58615.62166.285.18488.64181.524.58-60.48166.2845.2442.6243.1259.8535.6538.0316.64367.42166.6711.94610.71167.7133.26258.0278.6326.39399.8187.030.74261.82199.81
22Q4 (16)2610.02.350.64-91.97-35.350.88-89.01-29.611.595.75110.7331.72-41.1413.1644.12-34.98-5.613.56-86.52-9.411.68-91.92-33.339.29-80.96-18.725.28-86.31-41.222.02220.28172.50
22Q3 (15)2610.380.387.97532.54494.788.01434.0355.1110.96269.02141.4153.8985.1976.2367.8643.1949.8726.41438.98353.020.79533.84497.4148.80232.88215.6538.58242.63238.7238.62252.90207.76
22Q2 (14)2600.01.171.26-26.74-8.71.50-18.48-17.582.9772.67-7.4829.1-7.94-15.9947.399.2913.324.9-21.47-19.013.28-26.46-7.6114.66-21.274.9411.26-20.29.962.4123.5014.36
22Q1 (13)2601.967.01.7273.74-7.031.8447.2-15.61.72-68.73-7.0331.6112.77-4.943.36-7.23-3.716.2458.78-12.614.4676.98-0.6718.6262.94.3114.1157.134.522.2123.819.11
21Q4 (12)255-1.924.940.99-26.12-24.431.25-28.98-9.425.5021.1530.3328.03-8.34-10.4846.743.2210.033.93-32.59-12.282.52-27.59-20.7511.43-26.07-11.68.98-21.16-11.61-10.03-14.51-16.14
21Q3 (11)2601.177.01.34-2.916.521.76-3.328.474.5441.4355.4830.58-11.725.9645.288.274.125.83-3.6432.23.48-1.9724.7315.4610.6722.8911.3911.2317.91-3.76-14.15-9.91
21Q2 (10)2575.765.761.38-25.4112.21.82-16.5133.823.2173.5181.3634.644.2126.0141.82-7.133.516.05-15.2740.053.55-20.9418.7313.97-21.741.6710.24-24.15-6.485.197.9020.73
21Q1 (9)2430.00.01.8541.22242.592.1857.97113.731.85-56.16242.5933.246.1669.3345.036.0-1.877.1459.38144.524.4941.19240.1517.8538.05120.6413.5032.87101.197.3327.5629.35
20Q4 (8)2430.00.411.3113.91125.861.380.7384.04.2244.5254.0131.318.490.142.48-2.3213.194.481.5979.923.1813.98128.7812.932.78110.9310.165.18128.316.743.710.73
20Q3 (7)2430.00.01.15-6.540.241.370.7433.012.9264.9734.5628.864.9846.543.497.65-16.924.412.0851.032.79-6.6939.512.58-8.4410.649.66-11.78-4.8322.5160.6417.04
20Q2 (6)2430.00.01.23127.78515.01.3633.33248.721.77227.7831.1127.4940.0445.1440.40-11.96-20.584.3247.95242.862.99126.52522.9213.7469.84263.4910.9563.19298.181.4060.4434.66
20Q1 (5)2430.412.10.54-6.9-53.451.0236.0-19.690.54-80.29-53.4519.63-37.24-10.0845.8922.28-7.182.9217.27-34.531.32-5.04-52.08.0931.97-54.66.7150.79-48.97--0.00
19Q4 (4)242-0.410.00.58-29.270.00.75-27.180.02.7426.270.031.2858.780.037.53-28.310.02.49-14.730.01.39-30.50.06.13-46.090.04.45-56.160.0--0.00
19Q3 (3)2430.00.00.82310.00.01.03164.10.02.1760.740.019.74.010.052.352.910.02.92131.750.02.0316.670.011.37200.790.010.15269.090.0--0.00
19Q2 (2)2432.10.00.20-82.760.00.39-69.290.01.3516.380.018.94-13.240.050.872.890.01.26-71.750.00.48-82.550.03.78-78.790.02.75-79.090.0--0.00
19Q1 (1)2380.00.01.160.00.01.270.00.01.160.00.021.830.00.049.440.00.04.460.00.02.750.00.017.820.00.013.150.00.0--0.00
年/月營收月增率(%)去年同期年增率(%)累計營收累計營收年增率(%)近三月累計營收存貨銷售比備註(年增率變動50%需說明原因)
2024/210.52-47.29-3.1330.48-1.4844.2N/A-
2024/119.9645.41-0.5919.96-0.5945.03N/A-
2023/1213.7220.917.98169.5815.8934.191.1-
2023/1111.3524.55.94155.8616.6431.471.2-
2023/109.12-17.159.93144.5117.5731.971.18-
2023/911.0-7.12-67.14135.3918.1245.730.86本月營收較去年同期減少主係因去年血癌用藥集中於九月出貨基期較高,今年分散逐季出貨後,累計營收仍較去年同期成長。
2023/811.85-48.2118.86124.3853.3245.760.86本年累計營業收入較去年同期增長係因本年度血癌用藥Lenalidomide於美國市場銷售量增加所致。
2023/722.88107.4119.22112.5458.1547.130.83主係血癌用藥Lenalidomide於美國市場銷售量增加所致
2023/611.03-16.525.9989.6647.6644.420.88-
2023/513.22-34.4851.878.6356.2847.690.82主係美國市場客戶戒毒癮藥及血癌用藥Lenalidomide銷量增加所致
2023/420.1741.04101.8965.4157.2145.330.86美國市場客戶血癌用藥Lenalidomide補貨所致
2023/314.331.720.5245.2443.0945.240.79-
2023/210.86-45.915.5330.9456.6643.650.82一月份美國市場客戶血癌用藥Lenalidomide補貨所致
2023/120.0857.96112.2820.08112.2843.50.82美國市場客戶血癌用藥Lenalidomide補貨所致
2022/1212.7118.6339.03146.3315.6831.721.05-
2022/1110.7129.188.61133.6214.1952.50.63-
2022/108.29-75.23-4.48122.914.751.750.64-
2022/933.49235.96230.63114.6116.453.890.56血癌用藥Lenalidomide本期在美國上市銷售
2022/89.97-4.486.3881.12-8.1630.810.98-
2022/710.440.27-5.7971.15-9.8829.551.02-
2022/610.4119.55-9.5160.72-10.5529.11.07-
2022/58.71-12.87-24.7250.31-10.7730.561.02-
2022/49.99-15.8-13.6741.61-7.1632.150.97-
2022/311.8715.327.8331.61-4.931.611.0-
2022/210.298.781.2719.75-11.228.891.09-
2022/19.463.46-21.79.46-21.728.461.11-
2021/129.14-7.32-9.59126.1517.5827.691.11-
2021/119.8613.63.04117.0122.1628.671.07-
2021/108.68-14.27-15.15107.1424.2828.181.09-
2021/910.138.1-0.7698.4629.5930.580.84-
2021/89.37-15.4225.2688.3334.3231.950.8-
2021/711.08-3.67-0.878.9635.4834.140.75-
2021/611.5-0.559.367.8944.0834.640.79-
2021/511.57-0.0834.4456.3853.034.140.8外銷戒癮含片之美國終端市場份額較去年同期大幅增加
2021/411.575.1846.4444.8258.6632.740.83外銷戒癮含片之美國終端市場份額較去年同期大幅增加
2021/311.08.3157.4633.2463.433.240.66因去年第二季起新增東南亞市場業務、且旗下外銷戒癮含片之美國終端市場份額較去年同期大幅增加
2021/210.16-15.8995.422.2475.7532.350.68因去年第二季起新增東南亞市場業務、且旗下外銷戒癮含片之美國終端市場份額較去年同期大幅增加
2021/112.0819.4762.0512.0862.0531.760.69因去年第二季起新增東南亞市場業務、且旗下外銷戒癮含片之美國終端市場份額較去年同期大幅增加
2020/1210.115.63-41.69105.8915.4129.920.74-
2020/119.57-6.4531.4795.7827.4630.010.74-
2020/1010.230.2638.3586.227.0227.920.79-
2020/910.2136.4567.9375.9725.6428.850.59主要係因外銷業務持續成長、今年4月起新增東南亞市場業務,及去年底取得之授權品項陸續上市,使得營收較去年同期大幅成長
2020/87.48-33.0319.2865.7620.6829.170.58-
2020/711.176.1449.7857.8219.930.290.56-
2020/610.5222.3148.2446.6514.4427.030.55-
2020/58.68.8426.5936.134.6923.490.63-
2020/47.913.134.2127.55-0.6120.090.73-
2020/36.9934.416.8219.64-10.0119.640.66-
2020/25.2-30.25-48.6212.65-21.0530.00.43-
2020/17.45-57.0126.177.4526.1732.080.41-
2019/1217.34138.2227.2892.4843.8532.020.41外銷業務成長,去年同期部分產品未上市,又戒癮含片新增終端客戶與美國數州學名藥轉換,需求放大,經銷商為增加供貨彈性遂備貨
2019/117.28-1.5523.6875.1429.020.750.64-
2019/107.421.6939.5567.9729.7919.740.67-
2019/96.08-3.0711.6460.5728.6919.81.09-
2019/86.27-15.9120.3854.4930.9420.821.04-
2019/77.465.0544.6349.0734.7721.351.01-
2019/67.14.4519.7841.6133.1419.781.2-
2019/56.815.3920.6334.5136.1318.671.27五月營收中主要變動為韓國月衰17%、年衰20%,美國戒癮舌下含片月增300%。
2019/45.89-1.5522.1827.941.480.0N/A亞太(含韓國)、台灣與全球皆年增,亞太較上月衰退約10%,台灣月增雙位數,全球月增70%,其中美國產品戒癮含片月增130%
2019/35.98-40.8918.8922.0147.730.0N/A-
成長能力-近10年
加權平均股數 YoYEPS YoY本業EPS YoY營收 YoY毛利率(%) YoY營業利益 YoY稅前淨利 YoY稅後淨利 YoY
2023 (10)2610.015.6735.7914.9722.4169.5815.8955.343.7349.0319.2751.0329.5241.0635.92
2022 (9)2612.3511.54110.9712.2374.71146.3315.6953.3519.6541.1179.1339.4110.730.21115.32
2021 (8)2554.945.4729.627.0036.99126.4917.944.594.0822.9542.2818.743.414.0336.61
2020 (7)2430.414.2254.015.1150.74107.2911.6342.84-6.8916.1334.4213.0433.4710.2754.9
2019 (6)2421.682.74552.383.39130.6196.1149.4946.01-5.7812.0167.269.77495.736.63569.7
2018 (5)2380.00.42366.671.4714.8464.290.0848.831.864.49-18.071.64-30.510.99350.0
2017 (4)2380.00.0901.28341.3864.248.8347.94-14.975.48127.392.361375.00.220
2016 (3)2380.0-0.6300.29-69.4759.036.956.38-3.572.41-46.330.16-94.75-1.490
2015 (2)23830.050.4400.95055.22139.0558.4716.964.4903.0501.040
2014 (1)183200.0-2.410-1.11023.110.4249.990-4.350-5.870-4.420

財務分析相關資訊

免責聲明

本網站所有資料僅供參考,如使用者依本資料交易發生交易損失需自行負責,本網站對資料內容錯誤﹑更新延誤不負任何責任。